ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totaling 7,780 shares, a decline of 49.5% from the December 15th total of 15,418 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 44,325 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 44,325 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of ImmuCell in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell currently has an average rating of “Sell”.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC lifted its holdings in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 as of its most recent filing with the SEC. 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Stock Performance

Shares of NASDAQ ICCC traded up $0.02 during mid-day trading on Thursday, hitting $6.64. The company had a trading volume of 36,868 shares, compared to its average volume of 36,990. The stock’s 50-day moving average price is $5.74 and its 200-day moving average price is $6.13. ImmuCell has a 1 year low of $4.28 and a 1 year high of $7.60. The company has a market capitalization of $60.09 million, a price-to-earnings ratio of 25.54 and a beta of 0.18. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The business had revenue of $5.51 million during the quarter.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.